TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 antimicrobial-resistance report identifies 19 pathogens as concerning, serious or urgent threats, and puts six more on a watch list. Together, the pathogens are associated with an estimated 9.7 million U.S. infections and 50,800 deaths annually, according to the agency.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report names 19 pathogens as concerning, serious or urgent public-health threats and lists six additional organisms for monitoring. The agency estimates the pathogens together cause 9.7 million infections and 50,800 deaths in the United States each year, underscoring the continuing toll of infections that are difficult to treat with available drugs.
Four drug-resistant pathogens received the CDC’s highest category, “urgent threats”: Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The report groups pathogens by assessed threat level and calls for action against those at the highest tier.
The report includes estimates tied to individual organisms as well. In 2023, C. auris cases reported in the United States reached 4,523, up from 48 in 2016, when it was first reported. Carbapenem-resistant Acinetobacter was associated with an estimated 817 deaths and 9,497 U.S. hospitalizations in 2023; the CDC figures cited in the report indicate that 63% of those cases began outside hospitals.
Carbapenem-resistant Enterobacterales, which include some strains of E. coli and Klebsiella, were linked to 14,878 hospitalizations and an estimated 1,252 deaths in 2023. Drug-resistant gonorrhea is a different kind of challenge: the report estimates 787,000 U.S. infections in 2023 and says 55.4% of cases were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations.
The CDC’s category changes include drug-resistant N. meningitidis moving onto the serious-threat list. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria joined the watch list, which covers potential threats whose disease burden is uncertain. Clostridioides difficile moved down from urgent to serious; the report attributes that change in part to infection-prevention measures associated with declining case numbers since 2011.
Risks to Patients and Routine Care
Antimicrobial resistance can make infections harder to treat and can complicate care for people who are already medically vulnerable. Hospital and nursing-home patients may face particular risks from organisms that spread in care settings or affect people with ventilators, catheters or prolonged antibiotic exposure. The report’s estimates also show that the burden extends beyond hospitals, including infections that begin in the community.
Wendy Armstrong, president of the Infectious Diseases Society of America, said drug-resistant infections can prolong hospital stays and increase health-care costs. She also warned that resistance can make it harder for clinicians to safely provide treatments and procedures such as cancer chemotherapy, organ transplants and joint replacements. Those consequences are Armstrong’s assessment of the clinical impact, rather than a separate measure in the CDC’s annual estimates.
The report also points to pressure on the supply of effective treatments. Armstrong called for passage of the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs aimed at threatening infections. According to the source report, versions of the bill remained stalled in congressional committees as of publication.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Hyperice Normatec Elite Wireless Compression Boots
As an affiliate, we earn on qualifying purchases.
How the Threat List Changed
The CDC’s 2026 report updates the agency’s assessment of drug-resistant and other emerging pathogens. It places organisms into threat categories ranging from concerning and serious to urgent, while maintaining a separate watch list for potential threats where the disease burden is not yet clear. The classifications are intended to identify risks that warrant attention; they do not mean every listed pathogen poses the same likelihood of exposure or severity for every person.
Some of the reported figures refer to 2023 data, while others describe changes over a longer period. For example, the C. auris case count rose from 48 in 2016 to 4,523 in 2023. Those counts show the reported U.S. case totals for those years; the source material does not provide a separate comparison baseline for interpreting them as a rate of change.
The category shift for C. difficile is a reminder that threat assessments can change over time. The report says infection-prevention efforts have contributed to falling case numbers since 2011, helping move the organism from urgent to serious. That reclassification does not mean the infection is no longer a public-health concern.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Estimates and Watch List
The headline total is an agency estimate, not a count of every infection and death confirmed in a single year. The source material does not specify the precise measurement period or methods behind the combined annual estimate, so it should not be read as a real-time tally. Some organism-specific figures are explicitly for 2023 and should not be treated as current-year counts.
The CDC’s watch-list designation also signals uncertainty: the agency is monitoring six potential threats whose disease burden is not established in the report material. The available information does not give full case and death estimates for every pathogen, nor does it explain in detail how each category was determined. The figures for resistance in gonorrhea are not the same as a count of infections resistant to every antibiotic.
Monitoring, Prevention and Drug Policy
The CDC’s report sets out the agency’s updated assessment, but the source material does not identify a specific next publication date or announce a new federal response tied to its release. Public-health agencies and health-care providers will continue to monitor reported infections and resistance patterns, while infection-prevention measures remain part of efforts to reduce spread.
On drug development, Armstrong urged Congress to advance the PASTEUR Act. The bill’s status is a policy question separate from the CDC’s threat classifications; the source report says its versions remained in committee. The report also notes that the FDA approved gepotidacin and zoliflodacin in the previous year as new antibiotics for gonorrhea, but it does not provide further information here about their use or effect on resistance.
Key Questions
What does the CDC estimate about these pathogens?
The agency estimates that the pathogens covered by the report cause 9.7 million infections and 50,800 deaths in the United States annually. The source material does not specify the exact period or calculation method for the combined estimate.
Which pathogens are listed as urgent threats?
The four named urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower category?
The report moved Clostridioides difficile from urgent to serious, citing infection-prevention measures that have helped reduce case numbers since 2011. It remains on the serious-threat list.
What is the CDC watch list?
It tracks potential emerging threats for which the disease burden is uncertain. The 2026 report adds drug-resistant dermatophytes, drug-resistant H. influenzae and nontuberculous mycobacteria, among others.
What is the PASTEUR Act?
It is proposed federal legislation that Armstrong says would create a program to support development of antimicrobial drugs for threatening pathogens and infections. The source report says versions of the bill were stalled in congressional committees as of October 29, 2026.
Source: medpagetoday.com
